/IKNA
IKNA Stock - Ikena Oncology, Inc.
Healthcare|BiotechnologyNASDAQ
$17.16+1152.55%
+$15.79 (+1152.55%) • Jul 25
46
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.65
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).0
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-90.3%upside
Target: $1.66
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IKNA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$16.99 – $17.33
TARGET (TP)$1.67
STOP LOSS$15.79
RISK/REWARD1:-11.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.50
52W High$23.28
52W Low$1.36
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $9.16M | $15.62M | $30.98M | $9.19M |
| Gross Profit | $-490,000 | $8.14M | $13.58M | $-16,123,000 | $-35,653,000 |
| Gross Margin | N/A | 88.9% | 87.0% | -52.0% | -387.8% |
| Operating Income | $-58,973,000 | $-75,417,000 | $-70,904,000 | $-34,138,000 | $-44,519,000 |
| Net Income | $-49,234,000 | $-68,166,000 | $-68,765,000 | $-34,115,000 | $-44,256,000 |
| Net Margin | N/A | -744.2% | -440.3% | -110.1% | -481.4% |
| EPS | $-1.02 | $-1.63 | $-1.90 | $-0.95 | $-3.16 |
Company Overview
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
67%
Hold / Neutral
1
33%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
2 Bullish1 Neutral/Bearish
Price Targets
$10
Average Target
↓ 39.8% Downside
Now
$2
Low
$10
Average
$18
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| May 29th 2024 | Wedbush | Downgrade | Neutral | $2← $8 |
| September 22nd 2023 | Wedbush | Initiation | Outperform | $11 |
| May 4th 2023 | H.C. Wainwright | Resumed | Buy | $18 |
Earnings History & Surprises
IKNABeat Rate
68%
Last 19 quarters
Avg Surprise
-15.3%
EPS vs Estimate
Beats / Misses
13/5
1 met exactly
Latest EPS
$-0.53
Q4 2025
EPS Surprise History
Q1 24
0.0%
$-0.41vs$-0.41
Q2 24
+30.0%
$-0.28vs$-0.40
Q3 24
+12.9%
$-0.27vs$-0.31
Q4 24
+29.6%
$-0.19vs$-0.27
Q1 25
+5.3%
$-0.18vs$-0.19
Q2 25
+14.3%
$-0.18vs$-0.21
Q3 25
+57.1%
$-0.06vs$-0.14
Q4 25
-308.5%
$-0.53vs$-0.13
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 6, 2025 | $-0.13 | $-0.53 | -308.5% | ✗ MISS |
Q3 2025 | Jul 24, 2025 | $-0.14 | $-0.06 | +57.1% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.21 | $-0.18 | +14.3% | ✓ BEAT |
Q1 2025 | Mar 6, 2025 | $-0.19 | $-0.18 | +5.3% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.27 | $-0.19 | +29.6% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.31 | $-0.27 | +12.9% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-0.40 | $-0.28 | +30.0% | ✓ BEAT |
Q1 2024 | Mar 12, 2024 | $-0.41 | $-0.41 | 0.0% | = MET |
Q4 2023 | Nov 9, 2023 | $-0.44 | $-0.40 | +9.1% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.48 | $-0.44 | +8.3% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-0.46 | $-0.39 | +15.2% | ✓ BEAT |
Q1 2023 | Mar 14, 2023 | $-0.53 | $-0.39 | +26.4% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-0.50 | $-0.48 | +4.0% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.48 | $-0.57 | -18.7% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.42 | $-0.47 | -11.9% | ✗ MISS |
Q1 2022 | Mar 17, 2022 | $-0.51 | $0.07 | +113.7% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.41 | $-0.40 | +2.4% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-0.32 | $-0.35 | -9.4% | ✗ MISS |
Q2 2021 | May 13, 2021 | $-0.68 | $-2.52 | -270.6% | ✗ MISS |
Q1 2021 | Mar 26, 2021 | — | $-0.44 | — | — |
Latest News
Loading news...
Frequently Asked Questions about IKNA
What is IKNA's current stock price?
Ikena Oncology, Inc. (IKNA) is currently trading at $17.16 per share. The stock has moved +1152.55% today.
What is the analyst price target for IKNA?
The average analyst price target for IKNA is $1.67, based on 1 analyst.
What sector is Ikena Oncology, Inc. in?
Ikena Oncology, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is IKNA's market cap?
Ikena Oncology, Inc. has a market capitalization of $0.72 billion, making it a small-cap company.
Does IKNA pay dividends?
No, Ikena Oncology, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorASLN
ASLAN Pharmaceuticals Limited
$0.60
Mkt Cap: $0.2B
CDMO
Avid Bioservices, Inc.
$12.49
Mkt Cap: $0.8B
CMRX
Chimerix, Inc.
$8.54
Mkt Cap: $0.8B
EXAI
Exscientia plc
$4.84
Mkt Cap: $0.6B
ICPT
Intercept Pharmaceuticals, Inc.
$19.00
Mkt Cap: $0.8B
ICVX
Icosavax, Inc.
$15.31
Mkt Cap: $0.8B
ITOS
iTeos Therapeutics, Inc.
$10.15
Mkt Cap: $0.4B
IVVD
Invivyd, Inc.
$2.30
Mkt Cap: $0.3B
NAGE
Niagen Bioscience Inc
$6.52
Mkt Cap: $0.5B
SAGE
Sage Therapeutics, Inc.
$8.68
Mkt Cap: $0.5B
Explore stocks similar to IKNA for comparison